Recent advances in the development of P-gp inhibitors

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 415-436

  Baumert, Christiane ^a   Hilgeroth, Andreas ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Development; Multidrug resistance; P gp inhibitor

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARALKYLAMINE; CANNABINOID DERIVATIVE; CBT 1; CNIDIADIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLAVONOID; FLUOROURACIL; FUMITREMORGIN C; GLYCOPROTEIN P INHIBITOR; MM 36; PERVILLEINE F; PGP 4008; PROPAFENONE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; R 115776; TAMOXIFEN; TAXANE DERIVATIVE; TIPIFARNIB; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ZOSUQUIDAR; COUMARIN DERIVATIVE; DRUG DERIVATIVE; GLYCOPROTEIN P; PEPTIDE; PROPANOLAMINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; TERPENE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG RESISTANCE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COUMARINS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; P-GLYCOPROTEIN; PEPTIDES; PROPAFENONE; PROPANOLAMINES; PYRAZOLES; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TERPENES; VERAPAMIL;

EID: 67649786798     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909040415     Document Type: Review

References (145)

1. Morrow, C.S.; Cowan, K.H. In Cancer Medicine; Holland, J.F.; Frei, E.; Bast, J.C.; Kufe, D. W.; Morton, D.L.; Weichselbaum, R.R., Eds.; Williams & Wilkins; Hamilton, 1997, Vol. 4, pp. 799-815.
2. Liscovitch, M.; Lavie, Y. Cancer multidrug resistance: A review of recent drug discovery research. IDrugs, 2002, 5(4), 349-355.
3. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
4. Larsen, A.K.; Escarueil, A.E.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther., 2000, 85(3), 217-229.
5. Mitschler L.A.; Pillai, S.P.; Gentry E.J.; Shankel, D.M. Multiple drug resistance. Med. Res. Rev., 1999, 19(6), 477-496.
6. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 2000, 11(4), 265-283.
7. Goldman, B. Multidrug resistance: can new drugs help chemotherapy score against cancer? J. Natl. Cancer Inst., 2003, 95(4), 255-257.
8. Mahon, F. X.; Belloc, F.; Lagarde, V.; Chollet, C.; Moreau-Gaudry, F.; Reiffers, J.; Goldman, J. M.; Melo, J. V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 2003, 101(6), 2368-2373.
9. Matsui, H.; Takeshita, A.; Naito, K.; Shinjo, K.; Shigeno, K.; Maekawa, M.; Yamakawa, Y.; Tanimoto, M.; Kobayashi, M.; Ohnishi, K.; Ohno, R. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/ or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, 2002, 16(5), 813 819.
10. Gottesmann, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
11. Ozben, T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett., 2006, 580(12), 2903-2909.
12. Gottesmann, M. M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP- dependant transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
13. Gudmundsson, O.; Stouch, T.R. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev., 2002, 54(3), 315-328.
14. Bradley, G.; Juranka, P.F.; Ling, V. Mechanism of multidrug resistance. Biochim. Biophys. Acta, 1988, 948(1), 87-128.
15. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, J.J.; Roden, D.M. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 1998, 101(2), 289-294.
16. Linardi, R.L.; Natalini, C.C. Multi-drug resistance (MDR) gene and P-glycoprotein influence on pharmacokinetic and pharmacodynamic of therapeutic drugs. Ciênc. Rural., 2006, 36(1), 336-341.
17. Choi, C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int., 2005, 5, 30-42.
18. Marie, J.P.; Zittoun, R.; Sikic, B.I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 1991, 78(3), 586592.
19. List, A.F. Multidrug resistance: clinical relevance in acute Leukemia. Oncology, 1993, 7, 23-28.
20. Shitl, A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr. Drug Targets, 2001, 2(1), 57-77.
21. Varma, M.V.; Ashokraj, Y.; Dey, C.S.; Panchagnula, R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res., 2003, 48(4), 347-359.
22. Rosenberg, M.F.; Callaghan, R.; Modok, S.; Higgins, C.F.; Ford, R.C. Three- dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J. Biol. Chem., 2005, 280(4), 2857-2863.
23. Wollmann, J.; Richter, M.; Molnár, J.; Hilgeroth, A. First insight into the symmetry and flexibility of membrane efflux pump P-glycoprotein by novel bifunctional modulators. ChemBioChem, 2005, 6(8), 1353-1356.
24. Globisch, C.; Pajeva, I.K.; Wiese, M. Identification of putative binding sites of P- glycoprotein based on its homology model. Chem. Med. Chem, 2008, 3(2), 280-295.
25. Avendano, C.; Menéndez, J.C. Recent Advances in multidrug resistance modulators. Med. Chem. Rev.-Online, 2004, 1(4), 419-444.
26. Kawase, M.; Motohashi, N. New multidrug resistance reversal agents. Curr. Drug Tragets, 2003, 4(1), 31-43.
27. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 1981, 41(5), 1967-1972.
28. Teodori, E.; Dei, S.; Quidu, P.; Budriesi, R.; Chiarini, A.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Romanelli, M.N.; Scapecchi, S. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J. Med. Chem., 199, 42(10), 1687-1697.
29. Biscardi, M.; Teodori, E.; Caporale, R.; Budriesi, R.; Balestri, F.; Scappini, B.; Gavazzi, S.; Grossi, A. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. Leukemia Res., 2006, 30(1), 1-8.
30. Teodori, E.; Dei, S.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Martelli, C.; Romanelli, M.N.; Scapecchi, S.; Sudwan, P.; Salerno, M. Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. J. Med. Chem., 2005, 48(23), 7426-7436.
31. Teodori, E.; Martelli, C.; Salerno, M.; Darghal, N.; Dei, S.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Scapecchi, S.; Romanelli, M.N. Isomeric N,N- bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P- glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors. J. Med. Chem., 2007, 50(4), 599-602.
32. Dei, S.; Budriesi, R.; Sudwan, P.; Ferraroni, M.; Chiarini, A.; Garnier-Suillerot, A.; Manetti, D.; Martelli, C.; Scapecchi, S.; Teodori, E. Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators. Bioorg. Med. Chem., 2005, 13(4), 985-998.
33. Wu, D.L.; Yin, L.X.; Lu, H.Z. Reversal of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR by LY980503. World J. Gastroenterol., 2007, 13(15), 2234-2237.
34. Weiss, J.; Dormann, S.M.G.; Martin-Facklamm, M.; Kerpen, C.J.; Ketabi-Kiyanvash, N.; Haefeli, W.E. Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther., 2003, 305(1), 197-207.
35. Sorbera, L.A.; Castaner, J.; Sivestre, J.S.; Bayes, M. Zosuquidar trihydrochloride. Drugs Future, 2003, 28(2), 125-136.
36. Gerrard, G.; Payne, E.; Baker, R.J.; Jones, D.T.; Potter, M.; Prentice, H.G.; Ethell, M.; McCullough, H.; Burgess, M.; Mehta, A.B.; Ganeshaguru, K. Clinical effects and P- glycoprotein inhibition in patients with acute myeloid leukaemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica, 2004, 89(7), 782-790.
37. Saeki, T.; Nomizu, T.; Toi, M.; Ito,Y.; Noguchi, S.; Kobayashi, T.; Asaga, T.; Minami, H.; Yamamoto, N.; Aogi, K.; Ikeda, T.; Ohashi, Y.; Sato, W.; Tsuruo, T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with adversed or recurrent breast cancer. J. Clin. Oncol., 2007, 25(4), 411-517.
38. Schmid, D.; Staudacher, D.L.; Loew, H.G.; Spiekermann, P.G.; Ecker, G.F.; Kopp, S.; Chiba, P. A subset of highly effective propafenone-type multidrug resistance modulators lacks effects on cardiac action potential and mechanical twitch parameters of rat papillary muscles. J. Pharmacol. Exp. Ther., 2003, 307(2), 589-596.
39. Mistry, P.; Stewart, A.J.; Dangerfield, W.; Okiji, S.; Liddle, C; Bootle, D.; Plumb, J.A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 2001, 61(2), 749-758.
40. Jekerle, V.; Klinkhammer, W.; Scollard, D.A.; Breitbach, K.; Reilly, R.M.; Piquett- Miller, M.; Wiese, M. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int. J. Cancer, 2006, 119(2), 414-422.
41. Jekerle, V.; Klinkhammer, W.; Reilly, R.M., Piquette-Miller, M.; Wiese, M. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad- spectrum modulating properties. Cancer Chemother. Pharmacol., 2007, 59(1), 61-69.
42. Kang, H.; Fenical, W. Ningalins A-D: Novel aromatic alkaloids from a western australian ascidian of the genus didemnum. J. Org. Chem., 1997, 62(10), 3254-3262.
43. Soenen, D.R.; Hwang, I.; Hedrick, M.P.; Boger, D.L. Multidrug resistance reversal activity of key ningalin analogues. Bioorg. Med. Chem. Lett., 2003, 13(10), 1777-1782.
44. Hamasaki, A.; Zimpleman, J.M.; Hwang, I.; Boger, D.L. Total synthesis of ningalin D. J. Am. Chem. Soc., 2005, 127(30), 10767-10770.
45. Gangjee, A.; Yu, J.; Copper, J.E.; Smith, C.D. Discovery of novel antitumor antimitotic agents that also reverse tumor resistance. J. Med. Chem., 2007, 50(14), 3290-3301.
46. Singh, P.; Paul, K. Studies of interactions between uracil-based hybrid molecules and P- glycoprotein - Search for multidrug resistance modulators. Bioorg. Med. Chem., 2006, 14(21), 7183-7186.
47. Manna, F.; Chimenti, F.; Fioravanti, R.; Bolasco, A.; Secci, D.; Chimenti, P.; Ferlini, C.; Scambia, G. Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein. Bioorg. Med. Chem. Lett., 2005, 15(20), 4632-4635.
48. Das, U.; Molnár, J.; Zoltán, B.; Bata, Z.; Dimmock, J.R. 1-[4-(2-Aminoethoxy) phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: A novel series of highly potent revertants of P-glycoprotein associated multidnig resistance. Bioorg. Med. Chem. Lett., 2008, 18(12), 3484-3487.
49. Mihályi, A.; Gáspár, R.; Zalán, Z.; Lázár, L.; Fülöp, F.; De Witte, P.A.M. synthesis and multidrug resistance reversal activity of 1,2-disubstituted tetrahydroisoquinoline derivatives. Anticancer Res., 2004, 24, 1631-1636.
50. Li,Y.; Zhang, H.B.; Huang, W.L.; Li, Y.M. Design and synthesis of tetrahydro- isoquinoline derivatives as potential multidrug resistance reversal agents in cancer. Bioorg. Med. Chem. Lett., 2008, 18(12), 3652-3655.
51. Choi, S.U.; Park, S.H.; Kim, K.H.; Choi, E.J.; Kim, S.; Park, W.K.; Zhang, Y.H.; Kim, H.S.; Jung, N.P.; Lee, C.O. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anti-Cancer Drugs, 1998, 9(39), 255-261.
52. Wang, F.P.; Yang, J.S.; Nomura, M.; Miyamoto, K. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol. Pharm. Bull., 2005, 28(10), 1979-1982.
53. Robey, R.W.; Shukla, S.; Finley, E.M.; Oldham, R.K.; Barnett, D.; Ambudkar, S.V.; Fojo, T.; Bates, S.M. inhibition of P-glycoprotein (ABCB1)- and multidrug resistance- associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT- 1®. Biochem. Pharmacol., 2008, 75(6), 1302-1312.
54. Zhu, H.J.; Wang, J.S.; Guo, Q.L.; Jiang, Y.; Liu, G.Q. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol. Pharm. Bull., 2005, 28(10), 1974-1978.
55. Lee, B.D.; Li, Z.; French, K.J.; Zhuang, Y.; Xia, Z.; Smith C.D. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J. Med. Chem., 2004, 47(6), 1413-1422.
56. Medeiros, B.C.; Landau, H.J.; Morrow, M.; Lockerbie, R.O.; Pitts, T.; Eckhardt, S.G. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia, 2007, 21(4), 739-746.
57. Adams, M.; Mahringer, A.; Kuhnert, O.; Fricker, G.; Efferth, T.; Bauer, R. cytotoxicity and P-glycoprotein modulating effects of quinolones and indoloquinazolines from the chinese herb evodia rutaecarpa. Planta Med., 2007, 73(15), 1554-1557.
58. Yang, C.H.; Huang, C.J.; Yang, C.S.; Chu, Y.C.; Cheng, A.L.; Whang-Peng, J.; Yang, P.C. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res., 2005, 65(15), 6943-6949.
59. Dai, C.; Tiwari, A.T.; Wu, C.P.; Su, X.; Wang, S.R.; Liu, D.; Ashby, C.R.Jr.; Huang, Y.; Robey, R.W.; Liang, Y.; Chen, L.; Shi, C.J.; Ambudkar, S.V.; Chen, Z.S.; Fu, L. Lapatinib (Tykerb, GW572016) Reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res., 2008, 68(19), 7905-7914.
60. Liu, J.; Cui, G.; Zhao, M.; Cui, C.; Ju, J.; Peng, S. Dual-acting agents that possess reversing resistance and anticancer activities: design, synthesis, MES-SA/Dx5 cell assay, and SAR of Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo [3′,4′:1,2]pyridin- [3,4-b]indol-2-substitutedacetates. Bioorg. Med. Chem., 2007, 15(24), 7773-7788.
61. Boer, R.; Haas, S.; Schödl, A. Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. Eur. J. Cancer, 1994, 30A(8), 1117-1123.
62. Zhou, X.; Zhang, L.; Tseng, E.; Scott-Ramsay, E.; Schentag, J.J.; Coburn, R.A.; Morris, M.E. New 4-Aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab. Disp., 2005, 33(3), 321-328.
63. Loev, B.; Goodman, M.M.; Snader, K.M.; Tedeschi, R.; Macko, E. Hantzsch-type dihydropyridine hypotensive agents. J. Med. Chem., 1974, 17(9), 956-965.
64. Saponara, S.; Kawase, M.; Shah, A.; Motohashi, N.; Molnár, J.; Ugocsai, K.; Sgaragli, G.; Fusi, F. 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1, 4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility, Br. J. Pharmacol., 2004, 141(3), 415-422.
65. Voigt, B.; Coburger, C.; Molnár, J.; Hilgeroth, A. Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors. Bioorg. Med. Chem., 2007, [i 15(15), 5110-5113.
66. Richter, M.; Molnár, J.; Hilgeroth, A. Biological evaluation of bishydroxymethyl- substituted cage dimeric 1,4-dihydropyridines as a novel class of P-glycoprotein modulating agents in cancer cells. J. Med. Chem., 2006, 49(9), 2838-2840.
67. Mi, Q.; Cui, B.; Lantvit, D.; Reyes-Lim, E.; Chai, H.; Pezzuto, J.M.; Kinghorn, A.D.; Swanson, S.M. Pervilleine F, A new tropane alkaloid aromatic ester that reverses multidrug resistance. Anticancer Res., 2003, 23, 3607-3616.
68. Schmidt, M.; Ungvári, J.; Glöde, J.; Dobner, B.; Langner, A. New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance. Bioorg. Med. Chem., 2007, 15(6), 2283-2297.
69. Barthomeuf, C.; Grassi, J.; Demeule, M.; Fournier, C.; Boivin, D.; Béliveau, R. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother. Pharmacol., 2005, 56(2), 173-181.
70. Adams, M.; Mahringer, A.; Bauer, R.; Fricker, G.; Effort, T. In vitro cytotoxicity and P- glycoprotein modulating effects of geranylated furocoumarins from tetradium daniellii. Planta. Med., 2007, 73(14), 1475-1478.
71. Barthomeuf, C.; Demeule, M.; Grassi, J.; Saidkhodjaev, A.; Béliveau, R. Conferone from ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport. Planta Med., 2006, 72(14), 634-639.
72. Raad, I.; Terreux, R.; Richomme, P.; Matera, E.L.; Dumontet, C.; Raynaud, J.; Guilet, D. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter Pglycoprotein. Bioorg. Med. Chem., 2006, 14(20), 6979-6987.
73. Shen, X.; Chen, G.; Zhu, G.; Fong, W.F. (±)-3′ -O, 4′-O-dicynnamoyl-[i cis-khellactone, a derivative of (±)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Bioorg. Med. Chem., 2006, 14(21), 7138-7145.
74. Fong, W.F.; Shen, X.L.; Globisch, C.; Wiese, M.; Chen, G.Y.; Zhu, G.Y.; Yu, Z.L.; Tse, A.K.W.; Hu, Y.J. Methoxylation of 3′,4′- aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg. Med. Chem., 2008, 16(7), 3694-3703.
75. Quian, F.; Ye, C.L.; Wei, D.Z.; Lu, Y.H.; Yang, S.L. In vitro and in vivo reversal of cancer cell multidrug resistance by 2′,4′- dihydroxy-6′-methoxy-3′,5′-dimethyl-chalcone. J. Chemother., 2005, 17(3), 309-314.
76. Liu, X.L.; Tee, H.W.; Go, M.L. Functionalized chalcones as selective inhibitors of P- glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem., 2008, 16(1), 171-180.
77. Liu, X.L., Go, M.L. Antiproliferative activity of chalcones with basic functionalities. Bioorg. Med. Chem., 2007, 15(22), 7021-7034.
78. Hadjeri, M.; Barbier, M.; Ronot, X.; Mariotte, A.M.; Boumendjel, A.; Boutonnat, J. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J. Med. Chem., 2003, 46(11), 2125-2131.
79. Choi, C.H.; Kim, J.H.; Kim, S.H. Reversal of P-glycoprotein-mediated MDR by 5,7,3′,4′,5′ -pentamethoxyflavone and SAR. Biochem. Biophys. Res. Comm., 2004, 320(3), 672-679.
80. Lee, Y.; Yeo, H.; Liu, S.H.; Jiang, Z.; Savizky, R.M.; Austin, D.J.; Cheng, Y. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A Ring. J. Med. Chem., 2004, 47(22), 5555-5566.
81. Chan, K.F.; Zhao, Y.; Burkett, B.A.; Wong, I.L.K.; Chow, L.M.C.; Chan, T.H. Flavonoid dimers as bivalent modulators for Pglycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells. J. Med. Chem., 2006, 49(23), 6742-6759.
82. Džubák, P.; Hajdúch, M.; Gažák, R.; Svobodová, A.; Psotová, J.; Walterová, D.; Sedmera, P.; Křen, V. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg. Med. Chem., 2006, 14(11), 3793-3810.
83. Zhu, H.J.; Wang, J.S.; Markowitz, J.S.; Donovan, J.L.; Gibson, B.B.; Gefroh, H.A.; DeVane, L.J. Characterization of P-glyco-protein Inhibition by major cannabinoids from marijuana. Pharmacol. Exp. Ther., 2006, 317(2), 850-857.
84. Nieri, P.; Romiti, N.; Adinolfi, B.; Chicca, A.; Massarelli, I.; Chieli, E. Modulation of P- glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br. J. Pharmacol., 2006, 148(5), 682-687.
85. Fang, L.; Zhang, G.; Li, C.; Zheng, X.; Zhu, L.; Xiao, J.J.; Szakacs, G.; Nadas, J.; Chan, K.K.; Wang, P.G.; Sun, D. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. J. Med. Chem., 2006, 49(3), 932-941.
86. Batisti, R.F.; Zhong, Y.; Fang, Y.; Gibbs, S.; Shen, J.; Nadas, J.; Zhang, G., Sun, D. Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance. Mol. Pharm., 2006, 4(1), 140-153.
87. Sharom, F.J.; Yu, X.; Lu, P.; Liu, R.; Chu, J.W.K.; Szabó, K.; Müller, M.; Hose, C.D.; Monks, A.; Váradi, A.; Seprôdi, J.; Sarkadi, B. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem. Pharmacol., 1999, 58(4), 571-586.
88. Koubeissi, A.; Raad, I.; Ettouati, L.; Guilet, D.; Dumontet, C.; Paris, J. Inhibition of P- glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. Bioorg. Med. Chem. Lett., 2006, 16(21), 5700-5703.
89. Brooks, T.A.; Kennedy, D.R.; Gruol, D.L.; Ojima, I.; Baer, M.R.; Bernacki, R.J. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res., 2004, 24, 409-416.
90. Brooks, T.A.; Mindermann, H.; O'Loughlin, K.L.; Pera, P.; Ojima, I.; Baer, M.R.; Bernacki, R.J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther., 2003, 2(11), 1195-1205.
91. Ojima, I.; Borella, C.P.; Wu, X.; Bounaud, P.Y; Oderda, C.F.; Sturm, M.; Miller, M.L.; Chakravarty, S.; Chen, J.; Huang, Q.; Pera, P.; Brooks, T.A.; Baer, M.R.; Bernacki, R.J. Design, synthesis and structure - activity relationships of novel taxane-based multidrug resistance reversal agents. J. Med. Chem., 2005, 48(6), 2218-2228.
92. Mindermann, H.; Brooks, T.A.; O'Loughlin, K. L.; Ojima, I.; Bernacki, R.J., Baer, M.R. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother. Pharmacol., 2004, 53(5), 363-369.
93. Hasegawa, T.; Bai, J.; Dai, J.; Bai, L.; Sakai, J.; Nishizawa, S.; Bai, Y.; Kikuchi, M.; Abe, M.; Yamori, T.; Tomida, A.; Tsuruo, T.; Hirose, K.; Ando, M. Synthesis and structure- activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells. Bioorg. Med. Chem. Lett., 2007, 17(13), 3722-3728.
94. Hasegawa, T.; Bai, J.; Zhang, S:; Wang, J.; Matsubara, J.; Kawakami, J.; Tomida, A.; Tsuruo, T.; Hirose, K.; Sakai, J.; Kikuchi, M.; Abe, M.; Ando, M. Structure-activity relationships of some taxoids as multidrug resistance modulator. Bioorg. Med. Chem. Lett., 2007, 17(4), 1122-1126.
95. Corea, G.; Fattorusso, E.; Lanzotti, V.; Motti, R.; Simon, P.N.; Dumontet, C.; Di Pietro, Structure-activity relationships for euphocharacins A - L, a new series of jatrophane diterpenes, as inhibitors of cancer cell P-glycoprotein. Planta Med., 2004, 70(7), 657-665.
96. Corea, G.; Fattorusso, E.; Lanzotti, V.; Taglialatela-Scafati, O.; Appendino, G.; Ballero, M.; Simon, P.N.; Dumontet, C.; Di Pietro, A. Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a New, powerful lead. J. Med. Chem., 2003, 46(15), 3395-3402.
97. Corea, G.; Fattorusso, E.; Lanzotti, V.; Mottoi, R.; Simon, P.N.; Dumontet, C.; Di Pietro, A. Jatrophane diterpenes as modulators of multidrug resistance. advances of structure-activity relationships and discovery of the potent lead pepluanin A. J. Med. Chem., 2004, 47(4), 988-992.
98. Corea, G.; Fattorusso, E.; Lanzotti, V.; Taglialatela-Scafati, O.; Appendino, G.; Ballero, M.; Simon, P.N.; Dumontet, C.; Di Pietro, A. Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorg. Med. Chem., 2003, 11(23), 5221-5227.
99. Duarte, N.; Varga, A.; Cherepnev, G.; Radics, R.; Molnár, J.; Ferreira M.J.U. Apoptosis induction and modulation of P-glycoprotein mediated multidrug resistance by new macrocyclic lathyrane-type diterpenoids. Bioorg. Med. Chem., 2007, 15(1), 546-554.
100. Muñoz-Martinez, F.; Lu, P.; Cortés-Selva, F.; Pérez-Victoria, J.M.; Jiménez, I.A.; Ravelo, A.G.; Sharom, F.J.; Gamarro, F.; Castanys, S. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular rultidrug Resistance. Cancer Res., 2004, 64(19), 7130-7138.
101. Muñoz-Martinez, F.; Mendoza, C.R.; Bazzocchi, I.L.; Castanys, S.; Jiménez, I.A.; Gamarro, F. Reversion of human Pgp-dependent multidrug resistance by new sesquiterpenes from Zinowiewia costaricensis. J. Med. Chem., 2005, 48(13), 4266-4275.
102. Reyes, C.P.; Muñoz-Martinez, F.; Torrecillas, I.R.; Mendoza, C.R.; Gamarro, F.; Bazzocchi, I.L.; Núñez, M.J.; Pardo, L.; Castanys, S.; Campillo, M.; Jiménez, I.A. Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-β-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent Multidrug Resistance. J. Med. Chem., 2007, 50(20), 4808-4817.
103. Muñoz-Martinez, F.; Reyes, C.P.; Pérez-Lomas, A.L.; Jiménez, I.A.; Gamarro, F.; Castanys, S. Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific, non-transported inhibitors of human P-glycoprotein. Biochim. Biophys. Acta, 2006, 1758(1), 98-110.
104. Lee, C.A.; Floreancig, P.E. Studies in multidrug resistance reversal: a rapid and stereoselective synthesis of the dihydroagarofuran ring system. Tetrahedron Lett., 2004, 45(39), 7193-7196.
105. Madureira, A.M.; Spengler, G.; Molnár, A.; Varga, A.; Molnár, J.; Abreu, P.M.; ferreira, M.J.U. effect of cycloartanes on reversal of multidrug resistance and apoptosis induction on mouse lymphoma cells. Anticancer Res., 2004, 24, 859-864.
106. Wang, C.; Zhang, J.X.; Shen, X.L.; Wan, C.K.; Tse, A.K.W.; Fong, W.F. Reversal of P- glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem. Pharmacol., 2004, 68(5), 843-855.
107. Huang, Y.T.; Huang, D.M.; Chueh, S.C.; Teng, C.M.; Guh, J.H. Alisol B acetate, a triterpene from alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. Cancer Lett., 2006, 231(2), 270-278.
108. Sekiya, M.; Kashiwada, Y.; Nabekura, T.; Kitagawa, S.; Yamagishi, T.; Yokozawa, T.; Ichiyanagi, T.; Ikeshiro, Y.; Takaishi, Y. Effect of Triterpenoids Isolated from the Floral Spikes of Betula platyphylla var. japonica on P-Glycoprotein Function. Planta Med., [b 2007, 73(15), 1558-1562.
109. Jain, S.; Laphookhieo, S.; Shi, Z.; Fu, L.; Akiyama, S.; Chen, Z.S.; Youssef, D.T.A.; Van Soest, R.W.M.; El Sayed, K.A. Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. J. Nat. Prod., 2007, 70(6), 928-931.
110. Shen, L.Z.; Hua, Y.B.; Yu, X.M.; Xu, Q.; Chen, T.; Wang, J.H.; Wu, W.X. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J. Gastroenterol., 2005, 11(7), 1060-1064.
111. Romiti, N.; Pellati, F.; Nieri, P.; Benvenuti, S.; Adinolfi, B.; Chieli, E. P-glycoprotein inhibitory activity of lipophilic constituents of echinacea pallida roots in a human proximal tubular cell line. Planta Med., 2008, 74(3), 264-266.
112. Andrus, M.B.; Turner, T.M.; Asgari, D.; Li, W. The synthesis and evaluation of a solution-phase indexed combinatorial library of non-natural polyenes for multidrug resistance reversal. J. Org. Chem., 1999, 64(9), 2978-1979.
113. Andrus, M.B.; Turner, T.M.; Sauna, Z.E.; Ambudkar, S.V. The synthesis and evaluation of a solution phase indexed combinatorial library of non-natural polyenes for reversal of P-glycoprotein mediated multidrug mesistance. J. Org. Chem., 2000, 65(16), 4973-4983.
114. Sauna, Z.E.; Andrus, M.B.; Turner, T.M.; Ambudkar, S.V. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry, 2004, 43(8), 2262-2271.
115. Loo, T.W.; Clarke, D.M. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS- verapamil. J. Biol. Chem., 2001, 276(18), 14972-14979.
116. Aggarwal, B.B.; Kumar, A.; Bharri, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23(1A), 363-398.
117. Chearwae, W.; Anuchapreeda, S.; Nandigama, K.; Ambudkar, S.V.; Limtrakul, P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem. Pharmacol., 2004, 68(10), 2043-2052.
118. Lan, L.; Braiteh, K.S.; Kurzrock, R. Liposome-encapsulated curcumin. Cancer, 2005, 104(6), 1322-1331.
119. Limtrakul, P.; Chearwae, W.; Shukla, S.; Phisalphong, C.; Ambudkar, S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resiatnce protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem., 2007, 296(1-2), 85-95.
120. Um, Y.; Cho, S.; Woo, H.B.; Kim, Y.K.; Kim, H.; Ham, J.; Kim, S.N.; Ahn, C.M.; Lee, S. Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg. Med. Chem., 2008, 16(7), 3608-3615.
121. Dimmock, J.R.; Das, U.; Gul, H.I.; Kawase, M.; Sakagami, H.; Baráth, Z.; Ocsovsky, I.; Molnár, J. 3-Arylidene-1-(4-nitrophenylmethylene)- 3,4-dihydro-1H-naphthalen-2-ones and related compounds displaying selective toxicity and reversal of multidrug resistance in neoplastic cells. Bioorg. Med. Chem. Lett., 2005, 15(6), 1633-1636.
122. Das, U.; Kawase, M.; Skagami, H.; Ideo, A.; Shimada, J.; Molnár, J.; Baráth, Z.; Bata, Z.; Dimmock, J.R. 3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: A novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity. Bioorg. Med. Chem., 2007, 15(10), 3373-3380.
123. Leite, D.F.P.; Kassuya, C.A.L.; Mazzuco, T.L.; Silvestre, A.; De Melo, L.V.; Rehder, V.L.G.; Rumjanek, V.M.; Calixto, J.B. The cytotoxic effect and the multidrug resistance reversing action of lignans from phyllanthus amarus. Planta Med., 2006, 72(15), 1353-1358.
124. Pan, Q.; Lu, Q.; Zhang, K.; Hu, X. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol., 2006, 58(1), 99-106.
125. Pan, Q.; Wang, T.; Lu, Q.; Hu, X. Schisandrin B - A novel inhibitor of P-glycoprotein. Biochem. Biophys. Res. Commun., 2005, 335(2), 406-411.
126. Yoo, H.H.; Lee, M.; Lee, M.W.; Lim, S.Y.; Shin, J.; Kim, D.H. Effects of schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal caco-2 cells. Planta Med., 2007, 73(5), 444-450.
127. Schobert, R.; Kern, W.; Milius, W.; Ackermann, T.; Zoldakova, M. Synthesis of the first unnatural schisantherins and their effects in multidrug-resistant cancer cells. Tetrahedron Lett., 2008, 49(21), 3359-3362.
128. Min, H.Y.; Park, E.J.; Hong, J.Y.; Kang, Y.J.; Kim, S.J.; Chung, H.J.; Woo, E.R.; Hung, T.M.; Youn, U.J.; Kim, Y.S.; Kang, S.S.; Bae, K.H.; Lee, S.K. Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg. Med. Chem. Lett., 2008, 18(2), 523-526.
129. Heller, J.D.; Kuo, J.; Wu, T.C.; Kast, M.; Huang, R.C.C. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res., 2001, 62(14), 5499-5504.
130. 3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother. Pharmacol., 2006, 58(5), 640-653.
131. Regev, R.; Katzir, H.; Yeheskely-Hayon, D.; Eytan, G.D. Modulation of P-glycoprotein- mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J., 2007, 274(23), 6204-6214.
132. Sachs-Barrable, K.; Thamboo, A.; Lee, S.D.; Wasan, K.M. Lipid Excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 Cells. J. Pharm. Pharm. Sci., 2007, 10(3), 319-331.
133. Vock, C.A.; Ang, W.H.; Scolaro, C.; Phillips, A.D.; Lagopoulos, L.; Juillerat-Jeanneret, L.; Sava, G.; Scopelliti, R.; Dyson, P.J. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J. Med. Chem., 2007, 50(9), 2166-2175.
134. Heffeter, P.; Jakupec, M.A.; Korner, W.; Chiba, P.; Pirker, C.; Dornetshuber, R.; Elbing, L.; Sutterluty, H.; Micksche, M.; Keppler, B.K.; Berger, W. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem. Pharmacol., 2007, 73(12), 1873-1886.
135. Majumder, S.; Dutta, P.; Mukherjee, P.; Datta, E.R.; Efferth, T.; Bhattacharya, S.; Choudhuri, S.K. Reversal of drug resistance in Pglycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid. Cancer Lett., 2006, 244(1), 16-23.
136. Majumder, S.; Panda, G.S.; Choudhuri, S.K. Synthesis, characterization and biological properties of a novel copper complex. Eur. J. Med. Chem., 2003, 38(10), 893-898.
137. Molnár, J.; Musci, I.; Nasca, J.; Hevér, A.; Gyémént, N.; Ugocsai, K.; Hegyes, P.; Kiessig, S.; Gaal, D.; Lage, H.; Varga, A. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. Anticancer Res., 2004, 24, 865-872.
138. Fusi, F.; Ferrara, A.; Zalatnai, A.; Molnár, J.; Sgaragli, G.; Saponoara, S. Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells. Cancer Chemother. Pharmacol., 2008, 61(3), 443-451.
139. Cordo Russo, R.I.; García, M.G.; Alaniz, L.; Blanco, G.; Alvarez, E.; Hajos, S.E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/ Akt pathway. Int. J. Cancer, 2008, 122(5), 1012-1018.
140. Misra, S.; Ghatak, S.; Toole, B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem., 2005, 280(21), 20310-20315.
141. Wang, R.B.; Kuot, C.L.; Lien, L.L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther., 2003, 28(3), 203-228.
142. Chang, C.; Bahadduri, P.M.; Polli, J.E.; Swaan, P.W.; Ekins, S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab. Disp., 2006, 34(12), 1976-1984.
143. Huisman, M.T.; Smit, J.W.; Wiltshire, H.R.; Hoetelmans, R.M.W.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of Ritonavir. Mol. Pharmacol., 2001, 59(4), 806-813.
144. Taub, M.E.; Podila, L.; Ely, D.; Almeida, I. Functional assessment of multiple P- glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab. Dispos., 2005, 33(11), 1679-1687.
145. Coburger, C.; Wollmann, J.; Baumert, C.; Krug, M.; Molnár, J.; Lage, H.; Hilgeroth, A. Novel insight in structure activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes. J. Med. Chem., 2008, 51(18), 5871-5874.